*Refresh the page if the below document does not appear.
The five-member committee has an aim to develop a “legally enforceable” structure to regulate the marketing practices of pharmaceutical companies. The committee requires to submit its report in 90 days.
US regulatory authority finally approved the drug named “Pedmark” that can be used in treating hearing loss in kids due to chemotherapy. The company stated that the consent came more two years later than the expected date.
Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices (FSISDI-GP), Russia quoted that there is need for a new association as some organizations in the world get politically influenced and contravene on the rights of many countries.
After not getting expected results from federal appeals court ruling, the company has decided to question the US Supreme Court to uphold the validity of a patent it has for the dosing schedule of “Gilenya” for the treatment of multiple sclerosis.
The company will be facing a renewal scrutiny during November advisory comittee meeting over the “voluntary withdrawl” of one indication for its “Zejula” drug. The committee will be looking upon another approved use of the drug.
US arm of Zydus Lifesciences Limited named Sentynl Therapeutics and BridgeBio Pharma has jointly declared that the EU (European Commission) has granted marketing authority for NULIBRY (fosdenopterin) Injection indicated for molybdenum cofactor deficiency (MoCD) Type A.
The minister on Wednesday at Delhi mentioned
that the bulk drug Pharma Park will ensure not
only the retention of pharma formulation units in
the state but also will help create long term local
job opportunities.